期刊文献+

巴戟天寡糖胶囊用于轻、中度抑郁症患者巩固期治疗的临床研究

Clinical trial of Morinda officinalis oligosaccharides in the continuation treatment of adults with mild and moderate depression
原文传递
导出
摘要 目的观察巴戟天寡糖胶囊用于治疗轻、中度抑郁症患者的24周巩固期的疗效和安全性。方法本研究采用开放、单臂、多中心设计,纳入已完成巴戟天寡糖急性期治疗的成人轻、中度抑郁症患者,继续给予巴戟天寡糖胶囊24周,巩固期维持治疗剂量不变,用汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)、临床总体印象量表-严重度(CGI-S)和亚利桑那性体验量表(ASEX)评估治疗前后的变化,评估患者的缓解率、复燃率及复燃时间,观察患者治疗相关不良事件的发生情况。结果治疗前后患者的HAMD-17评分分别为(6.60±1.87)和(5.85±4.18)分,HAMA评分分别为(6.36±3.02)和(4.93±3.09)分,CGI-S评分分别为(1.49±0.56)和(1.29±0.81)分,ASEX评分分别为(15.92±4.72)和(15.57±5.26)分,在统计学上差异均有统计学意义(均P<0.05)。用药24周末,患者的缓解率为54.59%(202例/370例),复燃率为6.49%(24例/370例),复燃时间为(64.67±42.47)d。巴戟天寡糖胶囊药物不良反应发生率为15.35%(64例/417例)。结论巴戟天寡糖胶囊能用于轻、中度抑郁症患者的巩固期治疗,且具有良好的耐受性和安全性。 Objective To observe the efficacy and safety of Morinda officinalis oligosaccharides in the continuation treatment of mild and moderate depression.Methods An open,single-arm,multi-center design was adopted in our study.Adult patients with mild and moderate depression who had received acute treatment of Morinda officinalis oligosaccharides were enrolled and continue to receive Morinda officinalis oligosaccharides capsules for 24 weeks,the dose remained unchanged during continuation treatment.The remission rate,recurrence rate,recurrence time,and the change from baseline to endpoint of Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),Clinical Global Impression-Severity(CGI-S)and Arizona Sexual Experience Scale(ASEX)were evaluated.The incidence of treatment-related adverse events was reported.Results The scores of HAMD-17 at baseline and after treatment were 6.60±1.87 and 5.85±4.18,scores of HAMA were 6.36±3.02 and 4.93±3.09,scores of CGI-S were 1.49±0.56 and 1.29±0.81,scores of ASEX were 15.92±4.72 and 15.57±5.26,with significant difference(P<0.05).After continuation treatment,the remission rate was 54.59%(202 cases/370 cases),and the recurrence rate was 6.49%(24 cases/370 cases),the recurrence time was(64.67±42.47)days.The incidence of treatment-related adverse events was 15.35%(64 cases/417 cases).Conclusion Morinda officinalis oligosaccharides capsules can be effectively used for the continuation treatment of mild and moderate depression,and are well tolerated and safe.
作者 周书喆 韩祖成 王秀珍 陈燕清 呼亚玲 余雪芹 王斌红 樊国珍 桑红 海英 贾智捷 王占敏 魏琰 朱建国 宋学勤 刘志东 况利 王洪明 田峰 李玉欣 张玲 林海 吴斌 王超英 刘畅 孙佳凡 闫少校 刘君 谢守付 房茂胜 宓为峰 张鸿燕 ZHOU Shu-zhe;HAN Zu-cheng;WANG Xiu-zhen;CHEN Yan-qing;HU Ya-ling;YU Xue-qin;WANG Bin-hong;FAN Guo-zhen;SANG Hong;HAI Ying;JIA Zhi-jie;WANG Zhan-min;WEI Yan;ZHU Jian-guo;SONG Xue-qin;LIU Zhi-dong;KUANG Li;WANG Hong-ming;TIAN Feng;LI Yu-xin;ZHANG Ling;LIN Hai;WU Bin;WANG Chao-ying;LIU Chang;SUN Jia-fan;YAN Shao-xiao;LIU Jun;XIE Shou-fu;FANG Mao-sheng;MI Wei-feng;ZHANG Hong-yan(Office of Good Clinical Practice,Peking University Sixth Hospital,Peking University Institute of Mental Health,NHC Key Laboratory of Mental Health(Peking University),National Clinical Research Center for Mental Disorders(Peking University Sixth Hospital),Beijing 100191,China;Department of Psychiatry,Shaanxi Traditional Chinese Medicine Hospital,Xi’an 710003,Shaanxi Province,China;Department of Psychiatry,Shenyang Mental Health Center,Shenyang 110168,Liaoning Province,China;Department of Psychiatry,The Hospital of Shanxi University of Chinese Medicine Hospital,Taiyuan 030024,Shanxi Province,China;Department of Traditional Chinese Medicine,Shanxi Academy of Medical Science,Datong 037046,Shanxi Province,China;Department of Psychiatry,Chongqing Mental Health Center,Chongqing 400036,China;Department of Psychiatry,Taiyuan Psychiatric Hospital,Taiyuan 030045,Shanxi Province,China;Department of Psychiatry,Jilin Neuropsychiatric Hospital,Songyuan 138001,Jining Province,China;Department of Psychiatry,Changchun Sixth Hospital,Changchun 130052,Jilin Province,China;Department of Psychiatry,Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110033,Liaoning Province,China;Department of Psychiatry,Rongjun Hospital of Hebei Provence,Shijiazhuang 050899,Hebei Province,China;Department of Neurology,Hengshui People’s Hospital,Hengshui 053099,Hebei Province,China;Department of Psychiatry,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Hebei Province,China;Department of Psychiatry,Tianjin Fourth Central Hospital,Tianjin 300142,China;Department of Psychiatry,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400042,China;Department of Psychiatry,The Fourth People’s Hospital of Chengdu,Chendu 610036,Sichuan Province,China;Department of Psychiatry,Second Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province;Department of Psychiatry,The Mental Health Center of Hebei Provence,Baoding 071030,Hebei Province,China;Department of Psychiatry,Beijing Anding Hospital,Capital Medical University,Beijing 100120,China;Department of Psychiatry,Xi’an Traditional Chinese Medicine Hospital,Xi’an 710021,Shaanxi Province,China;Department of Psychiatry,Xi’an Mental Health Center,Xi’an 710061,Shaanxi Province,China;Department of Psychiatry,Brain Hospital of Hunan Provence,Changsha 410021,Hunan Province,China;Department of Psychiatry,The Tirst Hospital of Jilin University,Changchun 130061,Jilin Province,China;Department of Psychiatry,Shaanxi Integrated Hospital of Traditional Chinese and Western Medicine,Taiyuan 030013,Shanxi Province,China;Department of Psychiatry,Beijing Huilongguan Hospital,Beijing 102208,China;Department of Psychiatry,The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110034,Liaoning Province,China;Department of Psychiatry,Dalian Seventh People’s Hospital,Dalian 116086,Liaoning Province,China;Department of Psychiatry,Wuhan Mental Health Center,Wuhan 430012,Hubei Province,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2024年第6期815-819,共5页 The Chinese Journal of Clinical Pharmacology
基金 国家“重大新药创制”科技重大专项课题基金资助项目(2014ZX09301307014)。
关键词 巴戟天寡糖胶囊 抑郁症 疗效 安全性 Morinda officinalis oligosaccharides depression efficacy safety
  • 相关文献

参考文献4

二级参考文献43

共引文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部